Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Annick Diane Van Den Abbeele, M.D.

TitleAssociate Professor of Radiology
InstitutionDana-Farber Cancer Institute
DepartmentRadiology
AddressDana-Farber Cancer Institute
Dept. of Imaging
44 Binney St
Boston MA 02115
Phone617/632-3223
Fax617/582-8574

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012 Aug; 199(2):367-72.
    View in: PubMed
  2. George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 1; 30(19):2401-7.
    View in: PubMed
  3. Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 1; 83(5):e647-54.
    View in: PubMed
  4. Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med. 2012 Apr; 53(4):567-74.
    View in: PubMed
  5. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May 17; 119(20):4597-607.
    View in: PubMed
  6. Shinagare AB, Giardino AA, Jagannathan JP, Van den Abbeele AD, Ramaiya NH. Hereditary cancer syndromes: a radiologist's perspective. AJR Am J Roentgenol. 2011 Dec; 197(6):W1001-7.
    View in: PubMed
  7. Krajewski KM, Giardino AA, Zukotynski K, Van den Abbeele AD, Pedrosa I. Imaging in renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug; 25(4):687-715.
    View in: PubMed
  8. Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, Van den Abbeele AD. Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location. J Comput Assist Tomogr. 2011 Mar-Apr; 35(2):217-22.
    View in: PubMed
  9. Shinagare AB, Guo M, Hatabu H, Krajewski KM, Andriole K, Van den Abbeele AD, DiPiro PJ, Nishino M. Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer. 2011 Aug 15; 117(16):3860-6.
    View in: PubMed
  10. Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011 May; 59(5):856-62.
    View in: PubMed
  11. Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD. Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011 Apr; 18(4):424-36.
    View in: PubMed
  12. Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011 Jan; 196(1):117-22.
    View in: PubMed
  13. Hall MN, Jagannathan JP, Ramaiya NH, Shinagare AB, Van den Abbeele AD. Imaging of extraosseous myeloma: CT, PET/CT, and MRI features. AJR Am J Roentgenol. 2010 Nov; 195(5):1057-65.
    View in: PubMed
  14. Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62.
    View in: PubMed
  15. Shinagare AB, Jagannathan JP, Ramaiya NH, Hall MN, Van den Abbeele AD. Adult extragonadal germ cell tumors. AJR Am J Roentgenol. 2010 Oct; 195(4):W274-80.
    View in: PubMed
  16. Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8.
    View in: PubMed
  17. Lee AI, Zuckerman DS, Van den Abbeele AD, Aquino SL, Crowley D, Toomey C, Lacasce AS, Feng Y, Neuberg DS, Hochberg EP. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010 Aug 15; 116(16):3835-42.
    View in: PubMed
  18. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010 Aug; 195(2):281-9.
    View in: PubMed
  19. Kuppens S, Bossaert G, Buntinx W, Molleman C, Van den Abbeele A, Maes B. Factorial validity of the Supports Intensity Scale (SIS). Am J Intellect Dev Disabil. 2010 Jul; 115(4):327-39.
    View in: PubMed
  20. Souza FF, Fennessy FM, Yang Q, van den Abbeele AD. Case report. PET/CT appearance of desmoid tumour of the chest wall. Br J Radiol. 2010 Feb; 83(986):e39-42.
    View in: PubMed
  21. Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
    View in: PubMed
  22. Souza FF, Otero HJ, Erturk M, Rybicki FJ, Ramaiya N, Van den Abbeele AD, Di Salvo DN. Venous thrombosis in an outpatient oncologic center: distribution, type, and comorbidities. Ultrasound Q. 2009 Sep; 25(3):145-50.
    View in: PubMed
  23. Otero HJ, Jagannathan JP, Prevedello LM, Johnston CJ, Ramaiya NH, Van den Abbeele AD, DiPiro PJ. CT and PET/CT findings of T-cell lymphoma. AJR Am J Roentgenol. 2009 Aug; 193(2):349-58.
    View in: PubMed
  24. Otero HJ, Yap JT, Patak MA, Erturk SM, Israel DA, Johnston CJ, Sakellis C, Rybicki FJ, Van den Abbeele AD, Ros PR. Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. AJR Am J Roentgenol. 2009 Aug; 193(2):326-32.
    View in: PubMed
  25. Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul; 52(7):767-71.
    View in: PubMed
  26. Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009 Nov; 20(11):1848-53.
    View in: PubMed
  27. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 1; 27(19):3154-60.
    View in: PubMed
  28. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res. 2009 Mar 15; 15(6):1891-7.
    View in: PubMed
  29. Sheehy N, Kulke MH, Van den Abbeele AD. F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma. Clin Nucl Med. 2008 Aug; 33(8):545-6.
    View in: PubMed
  30. Erturk SM, Van den Abbeele AD. Role of PET/CT scanning in initial and post-treatment assessment of Hodgkin disease. J Natl Compr Canc Netw. 2008 Jul; 6(6):623-32.
    View in: PubMed
  31. Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma. 2008 May; 49(5):902-9.
    View in: PubMed
  32. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.
    View in: PubMed
  33. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
    View in: PubMed
  34. Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
    View in: PubMed
  35. Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF, Syngal S, Garber JE. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008 Mar 19; 299(11):1315-9.
    View in: PubMed
  36. Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist. 2008; 13 Suppl 2:8-13.
    View in: PubMed
  37. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007 Dec 15; 370(9604):2011-9.
    View in: PubMed
  38. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol. 2007 Dec; 189(6):W324-30.
    View in: PubMed
  39. El Fakhri G, Santos PA, Badawi RD, Holdsworth CH, Van Den Abbeele AD, Kijewski MF. Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body 18F-FDG PET. J Nucl Med. 2007 Dec; 48(12):1951-60.
    View in: PubMed
  40. Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6175-81.
    View in: PubMed
  41. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
    View in: PubMed
  42. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul; 5 Suppl 2:S1-29; quiz S30.
    View in: PubMed
  43. Khosa F.; Ramaiya N.; Johnston C.; Disalvo D.; Jagannathan J.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA. Imaging of Venous Thrombosis in Oncologic Patients. American Journal of Roentgenology(AJR). 2007; 188(5):E136-A115.
  44. Jagannathan J.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA. Missed Metastases-Causes and Clinical Relevance. American Journal of Roentgenology(AJR). 2007; 188(5):E145-A115.
  45. Jagannathan J.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA. Malignant Melanoma - Not Just Skin Deep!. American Journal of Roentgenology(AJR). 2007; 188(5):E140-A115.
  46. L. Syrkin, D. J. de Vries, G. Lefever, T. Locascio, Y. Kuzuhara, A. D. Van den Abbeele, J. T. Yap, Nuclear Medicine/PET, Dana-Farber Cancer Institute, Boston, Massachusetts.(333352). Deveolpment of a PET/CT database of patient information and scanning parameters. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):199P/701.
  47. N. Sheehy, I. A. David, A. D. Van den Abbeele, Radiology, Dana-Farber Cancer Institute, Boston, Massachusetts.(333139). Diagnosis of venous obstruction and thrombosis by radionuclinde venography in patients with central venous catheters. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):212P/1019.
  48. T. Locascio, Y. Kuzuhara, L. Syrkin, D. J. de Vries, G. Lefever, A. D. Van den Abbbeele, J. T. Yap, Division of Nuclear Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.(334084). PET/CT quality assurance in clinical trials and good clinical practice. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):448P/2012.
  49. G. Lefever, E. Andersen, J. T. Yap, A. D. Van den Abbeele, R. Tetrault; 1. Nucleare Medicine; 2. Environmental Health and Safety, Dana-Farber Cancer Institute, Boston, Massachusetts.(335244). Practical methods to minimize occupational radiation exposures in PET and nuclear medicine. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):452 p/2024.
  50. Ji H.; Fennessyu F.; Van den Abbeele A.; Ros P. Department of Radiology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Lymphoma: Differentiation of Lymphoma from Other Conditions. American Journal of Roentgenology(AJR). 2007; 188(5):A125.
  51. A. D. Van den Abbeele, J. T. Yap, D. S. Grayzel, J. Walker, G. D. Demetri; Dana-Farber Cancer Institute, Boston, MA; Infinity Pharmaceuticals Inc., Cambridge, MA. Inhibition and flare patterns of metabolic response to the heat shock protein 90(Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy. Journal of Clinical Oncology (JCO). 2007; 25(18S Part 1 of 2):145s/3530.
  52. G. D. Demetri, S. George, J. A. Morgan, A. Wagner, M. T. Quigley, K. Polson, J. Pokela, A. Van den Abbeele, J. Adams, D. Grayzel; Dana-Farber Cancer Institute, Boston, MA; Infinity Pharmaceuticals, Cambridge, MA. Inhibition of the heat Shock Protein 90(Hsp90) chaperone with the novel agent PIP-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase 1 trial. Journal of Clinical Oncology (JCO). 2007; 25(18S Part 1 of 2):551s/10024.
  53. Sheehy N.P.; Israel D.; Ramaiya N.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA. 18FDG-PET/CT in Soft Tissue Sarcoma: Looking Beyond GIST. American Journal of Roentgenology(AJR). 2007; 188(5):E429-A191-A195.
  54. Johnston C.; Ramaiya N.; Khosa F.; Van den Abbeele A. Dana-Farber Cancer Institute, Boston, MA. Radiological Response and Toxicity of the New Targeted Molecular Therapies for Cancer-What the Radiologist Needs to Know. American Journal of Roentgenology(AJR). 2007; 188(5):E419 A191-A195.
  55. Ji H.; Khosa F.; Van den Abbeele A. Department of Radiology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School., Boston, MA. Primary Malignant Neoplasms Mimicking Peritoneal Carcinomatosos: CT, MRI, and 18F FDG PET/CT Findings. American Journal of Roentgenology(AJR). 2007; 188(5):E207-A125-A140.
  56. Sheehy N, Fennessy F, Van den Abbeele A D. The Utility of 18F-FDG-PET in the Diagnosis and Management of Colorectal Carcinoma. Seminars in Colon and Rectal Surgery. 2007; In Press.
  57. Robert Levy. New core facility provides a common home for high-tech analysis of tumor images. Inside the Institute. 2007; 12(5):1.
  58. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006 Jun; 47(6):1059-66.
    View in: PubMed
  59. Lin NU, Carey LA, Liu MC, Come SE, Bullitt E, Van den Abbeele AD, Li X, Hochberg FH, Winer EP. Pahe II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. American Society of Clinical Oncology (ASCO). 2006; 24:3s.
  60. Van den Abbeele AD, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi RD, Demetri G. FDG-PET imaging demonstrates metabolic response to SU11248 (sunitinib malate) within 7 days in GIST patients resistant to or intolerant of imatinib mesylate. ICACT. 2006; 17:241.
  61. Raut CP, Van den Abbeele AD, Ramaiya N, Morgan JA, George S, Quigley MT, Dollard AM, Bertagnolli MM, Baum C, Demetri GD. Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). American Society of Clinical Oncology. 2006; 24:531s.
  62. Jacobsen E, Van den Abbeele AD, Neuberg D, Li S, Fisher DC, Friedberg J, Barnes AS, Yap JT, Kutok J, Freedman AS. Inhibiting TNF with etanercept in relapsed/refractory follicular lymphoma. American Society of Clinical Oncology (ASCO). 2006; 24:682s.
  63. Dileo P, Bauer S, Van den Abbeele AD, Morgan JA, George S, Salesi JM, Veronese L, Manley P, Fletcher JA, Demetri GD. Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; San Francisco, CA. 2006.
  64. Van den Abbeele AD, Barnes AS, de Vries DJ, Yap JT, Reichardt P, Casalli PG, Von Mehren M, O'Neel J, Hayes W, Demetri GD. Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST). American Society of Clinical Oncology (ASCO). 2006; 24:142s.
  65. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, vanSonnenberg E, Demetri G. Clonal Evolution of Resistance to Imatinib in Patients with Metastic GIST: Molecular and Radiologic Evaluation of New Lesions. 2006.
  66. Burrell SC, Van den Abbeele AD. 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: an atlas of normal uptake and variants. Mol Imaging Biol. 2005 May-Jun; 7(3):244-56.
    View in: PubMed
  67. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005 Jun; 235(3):892-8.
    View in: PubMed
  68. Dileo P, Van den Abbeele AD, Manola J, Desai J, Morgan JA, George S, St. Armand MW, Baum C, Demetri GD. Qualitative assessment of FDG PET correlates with clinical benefit in patients with imatinib mesylate-resistant GIST treated with multi-targeted tyrosine kinase inhibitor SU11248. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; Hollywood, FL. 2005.
  69. Van den Abbeele AD, Melenevsky Y, de Vries DJ, Manola J, Dileo P, Tetrault R, Baum C, Badawi R, Demetri GD. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). American Society of Clinical Oncology (ASCO); Orlando, FL. 2005.
  70. Van den Abbeele AD, Israel DA, Lechpammer S, Badawi RD. Tumor Ablation: Principles and Practice. 2005; 121-134..
  71. Van den Abbeele AD, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi RD, Demetri GD. FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate. The European Cancer Conference (ECCO 13); Paris, France. 2005.
  72. Ng AK, Bernardo MV, Silver B, Van Den Abbeele A, Stevenson MA, Fisher DC, Mauch PM. Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2005 Jan 1; 61(1):175-84.
    View in: PubMed
  73. Van den Abbeele AD, Israel DA, Lechpammer S, Badawi RD. Positron Emission Tomography Imaging for Tumor Ablation. Tumor Ablation: Principles and Practice. 2005; 121-134..
  74. Sullivan DC, Kelloff G. Seeing into cells: the promise of in vivo molecular imaging in oncology. 2005.
  75. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
    View in: PubMed
  76. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004 Sep 1; 10(17):5732-40.
    View in: PubMed
  77. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Tuncali K, Silverman SG, Van den Abbeele AD, vanSonnenberg E, Demetri GD. Clonal evaluation of resistance to imatinib in patients with gastrointestinal stromal tumor (GIST): Molecular and radiologic evaluation of new lesions. American Society of Clinical Oncology (ASCO)Conference. New Orleans, LA. 2004.
  78. Van den Abbeele AD, Badawi RD, Manola J, Morgan J, Desai J, Kazanovicz A, St Amand M, Baum C, Demetri GD. . Effects of cesssation of imatinib mesylate (IM) therapy in patients (pts) with IM-refactory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning. American Soceity of Clinical Oncology (ASCO) Conference. 2004.
  79. Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan JA, Tuncali K, Van den Abbeele A, Silverman SG, Demetri GD. . Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM). American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.
  80. Van Oosteram AT, Dumez H, Desai J, Stroobants S, Van den Abbeele A, Clement P, Shand N, Kovarik J, Tsyrlova A, Demetri GD. Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001)and imatinib mesylate (IM, Glivac/Gleevac) in patients with gastrointestinal stromal tumor (GIST)refractory to IM. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.
  81. Van den Abbeele AD, Badawi RD, Manola J, Morgan J, Desai J, Kazanovicz A, St. Amand M, Baum C, Demetri GD. Effects of cessation of imatinib mesylate therapy in patients with IM-refractory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.
  82. Van Oosteram AT, Dumez H, Desai J, Stroobants S, Van den Abbeele A, Clement P, Shand N, Kovarik J, Tsyrlova A, Demetri GD. . Combination signal transduction inhibition: a phase 1 and 2 trial of the oral mTOR-inhibitor everolimus (ERAD001) and imatinib mesylate (IM, Glivac r/Gleevac r) in patients (pts) with gastrointestinal stromal tumor (GIST) refactory to IM. American Society of Clinical Oncology (ASCO) Conference. 2004.
  83. Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A, Van den Abbeele A, Baum C, Maki R, Heinrich MC. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). New Orleans, LA. American Society of Clincal Oncology (ASCO) Conference. 2004.
  84. Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan JA, Tuncali K, Van den Abbeele A, Silverman SG, Demetri GD. Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (Pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM). American Society of Clinical Oncology (ASCO) Conference. 2004.
  85. Van den Abbeele AD. . The era of molecular therapy: redifining the treatment of gastrointestinal stromal tumors (GIST). 2004.
  86. Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A, Van den Abbeele A, Bacum C, Maki R, Heinrich MC. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by stromal tumor (GIST). American Society of Clinical Oncology (ASCO)Conference. 2004.
  87. Demetri GD, Benjamin R, Blanke CD, Choi H, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CD, Maki RG, Rubin BP, Van den Abbeele AD, von Mehren M. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2004 May; 2 Suppl 1:S-1-26; quiz 27-30.
    View in: PubMed
  88. Demetri GD, Benjamin R, Blanke CD, Haesun C, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CDM, Maki RG, Rubin B, Van den Abbeele AD, vonMehren M. Optimal management of patients with gastrointestinal stromal tumors (GIST). 2004.
  89. Desai J, Shankar S, Heinrich MC, Fletcher CD, Tuncali K, Silverman SG, Van den Abbeele AD, vanSonnenberg E, Demetri GD. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST). Molecular and radiologic evalution of new lesions. American Society of clinical Oncology (ASCO) Conference. 2004.
  90. Blanke C, Joensuu H, Demetri G, Heinrich M, Roberts P, Eisenberg B, Fletcher J, Fletcher C, Corless C, Dimitrijevic S, Van den Abbeele A, Kiese B, McDougall K, von Mehren M. Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Gastrointestinal Cancers Symposium; San Francisco, CA. 2004.
  91. Blanke C, Joensuu H, Demetri G, Heninrich M, Roberts P, Eisenberg B Fletcher J, Fletcher C, Corless C, Dimitrijevic S, Van den Abbeele A, Kiese B, McDougall K, von Mehren M. Long-term follow upof advanced gastrointestinal stromal tumors (GIST) patients treated with imatinib mesylate. Gastointestinal Cancers Symposium . 2004.
  92. Holdsworth CH, Manola J, Badawi RD, Israel DA, Blanke, C, von Mehren M, Joensuu H, Dimitrijevic S, Silberman S, Demetri GD and Van den Abbeele AD. Use of Computerized Tomography as an Early Prognostic Indicator of Response to Imatinib Mesylate in Patient with Gastrointestinal Stromal Tumors (GIST). Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. 2004.
  93. Van den Abbeele AD, Lechpammer S, Tetrault RJ, Badawi RD. Non-Hodgkin's Lymphomas. 2004; 155-169.
  94. Desai J, Shankar S, Heinrich MC, Fletcher JA, George S, Van den Abbeele AD, vanSonnenberg E, Demetri GD. A CME newsletter publication covering key clinical issues in the management of GIST, including highlights from the 2003 CTOS annual meeting and Helsinki GIST symposium. 2004.
  95. Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004 Jan; 45(1):85-92.
    View in: PubMed
  96. Desai J, Maki R, Heinrich MC, Fletcher JA, Ryan D, Morgan JA, St. Amand M, George S, Manola J, Baum C, Cohen DP, Corless CL, Fletcher CD, Van den Abbeele AD, Demetri GD. Activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU011248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; San Francisco, CA. 2004.
  97. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 1; 21(23):4342-9.
    View in: PubMed
  98. El Fakhri G, Holdsworth CH, Santos PA, Badawi RD, Van den Abbeele AD and Kijewski MF. . Impact of patients size, Acquisition mode, reconstruction algorithm, and random and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET. IEEE Medical Imaging Conference. 2003.
  99. Holdsworth CH, Badawi RD, Santos PA, Van den Abbeele AD and EI Fakhri G. Evaluation of a Monte Carlo scatter correction in clinical 3D PET. IEEE Medical Imaging Conference. 2003.
  100. EI Fakhri G, Holdsworth CH, Santos PA, Badawi RD, Van den Abbeele AD and Kijewski MF. . Impact of patient size, aquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estmiation in whole-body FDG-PET. IEEE Medical Imaging Conference. 2003.
  101. Radjahyaksha CD, D Neuberg S Li, Fischman AJ, Van den Abbeele AD. Prospective comparison of imaging finding in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD. Radiological Society of North America (RSNA) Conference. . 2003.
  102. El Fakhri G, Holdsworth CH, Santos PA, Badawi RD, Van den Abbeele AD and Kijewski MF. Impact of patient size, acquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET. IEEE Medical Imaging Conference. Portland, OR. 2003.
  103. Bindra J, Israel DA, Van den Abbeele AD. Physiologic and benign causes of FDG uptake in oncologic FDG-PET imaging. Radiological Society of North America (RSNA)Conference. 2003.
  104. Bindra J, Israel DA, Van den Abbeele AD. . Physiologic and benign causes of FDG uptake in oncologic FDG-PET imaging. Radiological Society of North America (RSNA) Conference. Chicago, IL. 2003.
  105. Radjadhyaksha CD, D Neuberg S Li, Fischman AJ, Van den Abbeele AD. Prospective comparison of imaging findings in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD. Radiological Society of North America (RSNA) Conference. Chicago, IL. 2003.
  106. Holdsworth CH, Badawi RD, Santos PA, Van den Abbeele AD and El Fakhri G. Evaluation of a Model Based Scatter Correction in Clinical 3D PET. IEEE Medical Imaging Conference. Portland, OR. 2003.
  107. Cherrington JM, Van den Abbeele A, Badawi RD, Lechpammer S, McCarthy TJ, Corless CL, ChoenDP, Scigalla P, Fletcher JA, and Demetri GD. Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib -resistant gastrointestinal stromal tumors (GIST):. Pharmacodynamic evaluation using 18 FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers. 2003.
  108. Cherrington JM, Van den Abbeele A, Badawi RD, Lechpammer S, McCarthy TJ, Manning WC, DePrimo SE, O'Farrell AM, Bello CL, Cohen DP, Scigalla P, Fletcher JA and Demetri GD. Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Pharmacodynamic evaluation using FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers. ISMRM Workshop on Cellular and Molecular Imaging in Diagnostics and Therapy. Orlando, FL. 2003.
  109. Skarin AT, Van den Abbeele AD. A New Role for PET Scanning. The American Journal of Oncology Reivew. 2003; 367-368.
  110. Van den Abbeele AD, Israel DA, Lechpammer S, Badawi RD. Pet Imaging: Tumor Ablation: Principles and Practice. 2003.
  111. DePrimo SE, Wong LM, Nicholas SL, Manning WC, O'Farrell AM, Amand M, McConarty B, Topciu R, Kazanovic A, Van den Abbeele AD, Demetri GD, Cherrington JM. Decreases in circulating levels of soluble KIT in patients with imatinib-resistant gastrointestinal Stromal tumor (GIST) receiving the novel kinases inhibitor SU11248: Correlative analysis of blood and plasma biomarkers. AACR. 2003; 44:587.
  112. Van den Abbeele AD, Lechpammer S, Tetrault RJ, Badawi RD. Non-Hodgkin's Lymphomas. Nuclear Medicine. 2003.
  113. Shaffer K, Van den Abbeele AD. Radiographic Evaluation of Cancer. Atlas of Diagnostic Oncology. 2003; 5-26.
  114. Demetri GD, Heinrich MC, George S, Manola J, Morgan JA, Desai J, St. Amand J, Cohen DP, Scigalla P, Manning WC, Cherrington JM, McCarthy TJ, Corless CL, Fletcher JA, Fletcher CDM, Van den Abbeele AD. Biological activity of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal Stromal tumor (GIST)refractory to imatinib mesylate. AACR. 2003; 44:967.
  115. Enzinger PC, Mayer RJ. Medical Progress, Esophageal Cancer. New Engl. J. Med. 2003.
  116. El Fakhri G, Holdsworth C, Badawi RD, Santos PA, Kijewski MF, Van den Abbeele AD, Moore SC. Dependence of performace of whole-body-FDG-PET lesion detection and activity estimation on patient size, randoms, variance reduction, and acquisition geometry. J Nucl Med. 2003; 44(5):61.
  117. Demetri GD, Heinrich MC, Fletcher JA, Fletcher CDM, George S, Desai J, Cohen DP, Scigalla P, Cherrington JM, Van den Abbeele AD. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol. 2003; 22:814A.
  118. Manning WC, Bello CL, DePrimo SE, Fletcher JA, Fletcher CDM, Van den Abbeele AD, Cohen DP, Scigalla P, Cherrington JM, Demetri GD. Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol. 2003; 22:192A.
  119. Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspective. 2003.
  120. Van den Abbeele AD, Badawi RD, Cliche JP, Spangler T, Janicek MJ, Israel DA, Heinrich MC, Silberman SS, Dimitrijevic S, Demetri GD. FDG-PET as a Surrogate Marker for the Response to Gleevec (Imatinib Mesylate) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST). J Nucl Med. 2003; 44(5):24-25.
  121. Shankar S, Desai J, Potter A, George S, Sherwood GK, Israel D, Dipiro P, Van den Abbeele AD, vanSonnenberg E, Demetri G. Novel patterns of progression following initial response to Imatinib in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2003; 22:230A.
  122. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002 Sep; 38 Suppl 5:S60-5.
    View in: PubMed
  123. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80.
    View in: PubMed
  124. Van den Abbeele AD, Burrell SC, McCollum D, Spangler TA, Haddad RI, Norris CM, Tishler RB, Posner MR. The role of FDG-PET in patients with squamous cell cancer of the head and neck after sequential induction chemotherapy and definitive chemoradiotherapy. J Nucl Med. 2002; 43:P73.
  125. Van den Abbeele AD. FDG-PET as a key tool in the diagnosis and monitoring of GIST. In first Successful Treatment for GIST. 2002.
  126. McCollum AD, Van den Abbeele AD, Haddad Rl, Burrell SC, Norris CM, Tishler RB, Case MA, Posner MR. The use of FDG-PET to detect residual disease after induction chemotherapy and definite chemoradiotherapy for squamous cell cancer of the head and neck. Sixth Research Workshop on the Biology,Prevention, and Treatment of Head and Neck Cancer. 2002.
  127. George D, Febbo P, Hagman E, OH W, Gilligan T, Lofa M, Weinstein M, Badawi RD, Van den Abbeele AD, Tempany C, Moricz M, Silberman S, Riche J, Kantoff P and Bubley G. A Pilot study Imatinib Mesylate prior to prostatectomy in men with newly diagnosed prostate cancer. 2002.
  128. George D, Febbo P, Hagman E, OH W, Gilligan T, Lofa M, Weinstein M, Badawi RD, Van den Abbeele AD, Tempany C, Moricz M, Silberman S, Richie J, Kantoff P and Bubley G. A Pilot study of Imatinib Mesylate (Gleevec) prior to prostatectomy in men with newly diagnosed prostate cancer. CaPCURE Scientific Retreat. 2002.
  129. Van den Abbeele AD, Badawi RD, Cliche JP, Israel D, Dimitrijevic S, Demetri G. Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT. Radiology. 2002; 225:P424.
  130. Van den Abbeele AD, Badawi RD, Cliche JP, Janicek M, Tetrault R, Spangler T, Potter A, Merriam P, Silberman S, Dimitrijevic S, Demetri GD. F-FDG-PET predicts response to Imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2002; 21:P403a.
  131. Badawi RD, El Fakhri G, Lechpammer S, Spangler TA, Tetrault RJ, Moore SC, Van den Abbeele AD. A comparison of 2D and 3D FDG-PET images on a high performance BGO scanner using an interleaved septa-in/septa-out acquisition protocol. Molecular Imaging and Biology. 2002; 4:44S.
  132. PET. Medstar. 2002.
  133. EI Fakhri G, Badawi RD, Santos PA, Moore SC, Van den Abbeele AD, Kijewski MF. Impact of acquisition geometry and size on tumor detectability in patient whole body PET:. A Channelized hotelling observer study. 2002.
  134. Van den Abbeele AD, Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Mauch P and Canellos GP. FDG-PET is superior to gallium-67 scintigraphy in the staging and follow-up of patients with Hodgkin's disease: a prospective, blinded comparison. J Nucl Med. 2002; 43:P30-P31.
  135. Lechpammer S, Tetrault RJ, Badawi RD, Van den Abbeele. PET imaging and treatment evaluation in cancer patients. 2002.
  136. El Fakhri G, Badawi RD, Santos PA, Moore SC, Van den Abbeele AD, Kijewski MF. Impact of acquisition geometry and lesion size on tumor detectability in patient whole body PET: A channelized hotelling observer study. IEEE meeting. 2002.
  137. A day in the life of the Dana-Farber Cancer Institute. 2001.
  138. McCollum D, Van den Abbeele AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Lake-Willcutt B, Posner MR. The use of FDG-PET to detect residual disease after sequential therapy with induction chemotherapy and definitive chemoradiotherapy for squamous cell cancer of the head and neck. The Second International Chicago Symposium on Malginancies of the Chest and Head & Neck. 2001; abst. 76.
  139. McCollum D, Van den Abbeele AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case Ma, Lake-Willcutt B, Posner MR. The use of FDG-PET to detect residual disease after sequential therapy with induction chemotherapy and definitive chemoradiotherapy for squamous cell cancer of the head and neck. The second International Chicago Symposium on Malignancies of the Chest and Head and neck. 2001.
  140. Friedberg JW, Canellos GP, Neuberg D, Kim H, Mauch P, Van den Abbeele. A prospective blinded comparison of positron emission tomography(PET)with gallium/SPECT scintigraphy in the staging and follow-up of patients with de novo Hodgkin's disease. International Lymphoma Conference, Lausanne. 2001.
  141. Friedberg JW, Canellos GP, Neuberg D, Kim H, Mauch P, Van den Abbeele. A prospective blind comparison of positron emission tomography (PET) with gallium/SPECT scintigraphy in the staging and follow up of patients with de novo Hodgkin's disease. 2001.
  142. The role of PET in patients with GIST. 2001.
  143. The role of PET in patients with cancer. 2001.
  144. GIST tumors and Glivec. 2001.
  145. Losken A, Swartz MA, Van Den Abbeele AD, Jain RK, Slavin SA. A potential murine model for flap-related investigations. Plast Reconstr Surg. 2001 May; 107(6):1504-8.
    View in: PubMed
  146. The Power of Positron Emission Tomography (PET). 2001.
  147. Van den Abbeele AD, for the GIST Collaborative PET Study Group. F18-FDG-PET provides early evidence of biological response to ST1571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2001; 20:P362a.
  148. PET documents Gleevec tumor-fighting power. Diagnostic Imaging. 2001; 1(2):4.
  149. Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD. Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer. 2001 Jan 1; 91(1):17-24.
    View in: PubMed
  150. Breast Cancer. 2001.
  151. Frank DA, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD. The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis. 2000 Dec; 10(3):271-5.
    View in: PubMed
  152. Uncovering Cancer. The use of radioactive tracers. 2000.
  153. PET scanners. 2000.
  154. Frohlich DE, Chen JL, Neuberg D, Kehoe KM, Van den Abbeele AD. When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy? J Nucl Med. 2000 Feb; 41(2):269-74.
    View in: PubMed
  155. Jones A. Positron Emission Tomography (PET). 2000.
  156. Donohoe D, Van den Abbeele A. Teaching Atlas of Nuclear Medicine. 2000.
  157. Van den Abbeele AD. Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. 2000; 199-216.
  158. Van den Abbeele AD, Fey CP. Vascular Scintigraphy. Teaching Atlas of Nuclear Medicine. 2000; 429-439.
  159. Janicek MJ, Fey CP, Van den Abbeele AD. Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele. 2000; 235-246.
  160. VanSonnenberg E, Silverman SG, Shankar S, Tuncali K, Van den Abbeele AD, Meyerovitz M, Whang E. . Large and multiple hepatic Lesions. Strategies and rationale for radiologic tumor ablation. 2000.
  161. Fey CP, Van den Abbeele AD. Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele. 2000; 224-234.
  162. VanSonnenberg E, Silverman SG, Shankar S, Tuncali K, Van den Abbeele AD, Meyerovitz M, Whang E. Large and multiple hepatic lesions: Strategies and rationale for radiologic tumor ablation. RSNA Annual Meeting. 2000.
  163. Moore SC, El Fakhri G, Badawi R, Van den Abbeele AD, Zimmerman RE. Relative lesion detectability in 3D vs. 2D dedicated multi-ring PET. IEEE meeting 2000, Lyon, France. 2000.
  164. McCollum AD, Van den Abbeele AD, Haddad RI, Burrell SC, Norris CM, Tishler RB, Case MA, Posner MR. The use of FDG-PET to detect residual disease after induction chemotherapy and definite chemoradiotherapy for squamous cell cancer of the head and neck. Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer. Virginia. 2000.
  165. Moore SC, EI Fakhri G, Badawi R, Van den Abbeele AD, Zimmerman RE. . Relative Lesion detectability in 3D vs. 2D dedicated multi-ring PET. 2000.
  166. Van den Abbeele AD. Lymphoscintigraphy. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele A. 2000; 369-374.
  167. PET scanner is enhancing cancer diagnosis. 2000.
  168. Advances at the Frontier of Cancer Diagnosis: PET scanner opens a window on cancer. Paths of Progress. 2000.
  169. Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999 Oct 15; 86(8):1621-7.
    View in: PubMed
  170. Slavin SA, Van den Abbeele AD, Losken A, Swartz MA, Jain RK. Return of lymphatic function after flap transfer for acute lymphedema. Ann Surg. 1999 Mar; 229(3):421-7.
    View in: PubMed
  171. Wu C, Vasconcelles M, DePiro P, Van den Abbeele A, Rakusin A, Bechard K, Skarin A. Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. J Clin Oncol. 1998 Dec; 16(12):3913-5.
    View in: PubMed
  172. Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR, Matalka KZ, Cook CU, Sahu SK, Black PM, Adelstein SJ. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med. 1998 Jul; 39(7):1148-54.
    View in: PubMed
  173. Borras-Boneu G, Van den Abbeele AD, Kassis AI. Biodistribution of radiolabeled MOv18 in nude mice bearing ovarian cancer xenografts. Proceeding of the Fourth International Conference on Monoclonal Antibody lmmunoconjugates for Cancer. 1998; 97.
  174. Wagenaar DJ, Zimmerman RE, Hill TC, Kolodny GM, Van den Abbeele AD. . Comparison of Dual-Head Gamma Camera System Sensitivity at 511 KeV using a Distance-Dependent Method. American Association of Physicists in Medicine a 39th Annual Meeting and Exhibition. 1997.
  175. Wagenaar DJ, Zimmerman RE, Hill TC, Kolodny GM, Van den Abbeele AD. Comparison of Dual-Head Gamma Camera System Sensitivity at 511 keV using a Distance-Dependent Method. American Association of Physicists in Medicine 39th Annual Meeting and Exhibition. Milwaukee, WI. 1997.
  176. Bartold SP, Donohoe KJ, Fletcher JW, Haynie TP, Henkin RE, Silberstein EB, Royal HD, Van den Abbeele A. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine. J Nucl Med. 1997 Jun; 38(6):990-4.
    View in: PubMed
  177. Slavin SA, Upton J, Kaplan WD, Van den Abbeele AD. An investigation of lymphatic function following free-tissue transfer. Plast Reconstr Surg. 1997 Mar; 99(3):730-41; discussion 742-3.
    View in: PubMed
  178. Van den Abbeele AD, Rybicki FJ, Cowart DM, Kehoe KM. Quantification of gallium-67 avidity as a function of the histology in patients with non-Hodgkin's lymphoma. J Nucl Med. 1997; 38:P238.
  179. Van den Abbeele AD, Shulkin BL, Neuberg DS, Kehoe KM. The role of SPECT in the evaluation of the abdomen on gallium-67 scintigraphy. J Nucl Med. 1997; 38:P115.
  180. Wagenaar DJ, Golden E, Van den Abbeele AD, kolodny GM. Determinination of the visibility of simulated lesions in background with 511 KeV SPECT. Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer. 1996.
  181. Wagenaar DJ, Golden E, Van den Abbeele AD, Kolodny GM. Determination of the visibility of simulated lesions in background with 511 keV SPECT. European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer, Groningen University Hospital, The Netherlands. 1996.
  182. Kassis AI, Tumeh SS, Wen PY, Baranowska-Kortylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garada BM, DeSisto WC, Bailey NO, Castronovo FP, Mariani G, Black PM, Adelstein SJ. Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med. 1996 Apr; 37(4 Suppl):19S-22S.
    View in: PubMed
  183. Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med. 1996 Feb; 37(2):315-20.
    View in: PubMed
  184. Kassis AI, Tumeh SS, Wen PYC, Baranowska-Korylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garade BM, DeSisto WC, Baily NO, Castronovo FP,Mariani G, Black PMcL, Adelstein SJ. . Intratumoral administration of 5-[123/]iodo-2-deoxyurdine in a patients with a brain tumor. Adelstein SJ, Kassis AI, eds. Processing of symposium on clinical application of radiolabeled IUdR. 1996; 37:(Suppl) 19S-22S.
  185. Nagel JS, Van den Abbeele AD. Scrontium-89 radiotherapy for painful bony metastases. 1996.
  186. Van den Abbeele AD, Slavin SA. Classification of upper extremity lymphedema via lymphoscintigraphy. J Nucl Med. 1996; 37:P261.
  187. Van den Abbeele AD. Tumor and Inflammatory conditions. 1996.
  188. Van den Abbeele AD, Scheiner JD. Lymphoscintigraphy. 1996.
  189. Van den Abbeele AD. Octreotide scintigraphy. 1996.
  190. Arthur JE, Kehoe K, Van den Abbeele AD. . Thallium-201 scintigraphy in low grade non-Hodgkin's lymphoma. J Nucl Med. 1996; 37:P258.
  191. Wagenaar DJ, Golden E, Van den Abbeele AD, Kolodny GM. Determination of the visibility of simulated lesions in background with 511 KeV SPECT. In Paans AMJ, Pruim J, Franssen EJF, Vaalburg W, eds.+. Metabolic imaging of cancer. Proceedings of the Europeans Conference on Research and Application of Positron Emission Tomography in Oncology. 1996.
  192. Wagenaar DJ, Van den Abbeele AD, Kolodny GM, Hill TC, Zimmerman RE. A world wide web-based resource for the physical evaluation of 511 keV-collimated imaging. J Nucl Med. 1996; 37:P305.
  193. Nagel JS, Van den Abbeele AD. Scrontium-89 radiotherapy for painful bony metastases. 1996.
  194. A Patient Guide to Nuclear Medicine at the Dana-Farber Cancer Institute. Divsion of Nuclear Medicine at the DFCI. 1996.
  195. Gangopadhyay A, Saravis CA, van den Abbeele AD, Kassis AI. pI-dependent isolation of antibody isoforms by semipreparative isoelectric focusing. Q J Nucl Med. 1995 Jun; 39(2):129-33.
    View in: PubMed
  196. Van den Abbeele AD, Craveiro EM, Manganella JH, Kaplan WD. Lymphatic imaging and its multiple roles in clinical practice. J Nucl Med. 1995; 36:P222.
  197. Van den Abbeele AD. . Scintigraphy of lymphoma. 1995.
  198. Buonomo C, Van den Abbeele AD. Inflammation and infection. Pediatric Nuclear Medicine. 1995; 540-549.
  199. Van den Abbeele AD. Monoclonal antibodies: A review of the basics. 1994.
  200. Gangopadhyay A, Van den Abbeele AD, Kassis AI. Modification of Mouse IgG isoelectric point following radioiodination. Antibody Immunoconj Radiophar. 1994; 7:171-178..
  201. Mariani G, Collecchi P, Giuliani L, Baranowska-Kortylewicz J, Di Luca L, Meucci G, Viacava P, Van den Abbeele AD, Salvadori PA, Di Sacco S, et al. Tumor targeting potential and metabolism of 5-[125I]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancer. Ann N Y Acad Sci. 1993 Nov 30; 698:204-11.
    View in: PubMed
  202. Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Kassis AI. . A new three-step strategy using the avidin-biotin system for radioimaging tumors. Abstracts of the Tenth International Symposium in Radiopharmaceutical Chemistry,. 1993; 392-3.
  203. Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Kassis Al. A new three-step strategy using the avidin-biotin system for radioimaging tumors. Abstracts of the Tenth International Symposium on Radiopharmaceutical Chemistry, Kyoto, Japan. 1993; 392(3).
  204. Mariani G, Cei A, Collecchi P, Baranowska-Kortylewicz J, Van den Abbeele AD, Di Luca L, Di Stefano R, Viacava P, Ferdeghini EM, Di Sacco S, et al. Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med. 1993 Jul; 34(7):1175-83.
    View in: PubMed
  205. Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz, Jones PL, Lambrecht RM, Adelstein SJ, Black PMcL, Kassis AI. A three-step procedure for the targeting of tumors using the avidin-biotin system. Presented at the Australia/ New Zealand Society of Nuclear Medicine scientific Meeting. 1993.
  206. Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Black PMcL, Kassis Al. A three-step procedure for the targeting of tumors using the avidin-biotin system. Australia/New Zealand Society of Nuclear Medicine Scientific Meeting, Canberra, Australia. 1993.
  207. Van Den Abbeele AD. Monoclonal antibodies: From basics to clinical implementation. 1993.
  208. Mariani G, Collecchi P, Giuliani L, Baranowska-Kortylewicz J, Di Luca L, Meucci G, Viacava P, Van den Abbeele AD, Salvadori PA, Di Sacco S, Adelstein SJ, Bevilacqua G, Kassis AI. . Tumor targeting potential and metabolism of 5-[125]iodo 2-deoxyuridine injected intratumorally in patients with breast Cancer. Ann NY Acad sc. 1993; 698:204-11.
  209. Mariani G, Giuliani L, Baranowska-Kortylewicz J, Collecchi P, Meucci G, Di Luca L, Viacava P, Van den Abbeele AD, Bevilacqua G, Salvadori PA, Adelstein SJ, Kassis AI. Intratumoral injection of 5[123]iodo-2-dexyuridine in patients with breast cancer. In Hofer R, Bergmann H, Sinzinger H, eds. Radioactive isotopes in clinical medicine and research. 1993; 188-93.
  210. Khawli LA, van den Abbeele AD, Kassis AI. N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies. Int J Rad Appl Instrum B. 1992 Apr; 19(3):289-95.
    View in: PubMed
  211. Mariani G, Cei A, Giuliani L, Baranowska-Kortylewicz J, Collecchi P, Meucci G, Di Lucca L, Viacava P, Van den Abbeele AD, Bevilacqua G, Salvadori PA, Adelstein SJ, Kassis AI. Tumor targeting potential and metabolism of 5-[125]iodo-2-deoxyurdine injected intratumorally in patients with gastrointestinal or breast cancers. J Nucl Biol Med. 1992; 154-7.
  212. Van den Abbeele AD, Baranowska-Kortylewicz J, Adelstein SJ, Carvalho PA, Tutrone RF, Riche JP, Wen PYC, Black PMcL, Mariani G Kassis AI. Diagnostic and therapeutic application of Auger-electrons-emitting 5[123/125]iodo-2-deoxyuridine in cancer. In Howell RW, Narra VR, Sastry KSR, Rao DV, eds Biophysical aspect of Auger processes, AAPM Symposium Proceeding number 8. 1992; 372-395.
  213. Baranowska-Kortylewicz J, Makrigiorgos GM, Van den Abbeele AD, Berman RM, Adelstein SJ, Kassis AI. 5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys. 1991 Nov; 21(6):1541-51.
    View in: PubMed
  214. Van den Abbeele AD, Baranowska- Kortylewicz J, Mariani G, Adelstein SJ, Kassis AI. Diagnostic and therapeutic applications of the Auger electrons-emitting 5-[123/125/]iodo-2-deoxyuridine in cancer. Presented at the Second International Symposium on Biophysical Aspect of Auger Processes, Amherst. 1991.
  215. Van den Abbeele AD, Baranowska-Kortylewicz J, Mariani G, Adelstein SJ, Kassis Al. Diagnostic and therapeutic applications of the Auger electron-emitting 5-[123/125/]iodo-2'-deoxyuridine in cancer. Second International Symposium on Biophysical Aspects of Auger Processes, Amherst, MA. 1991.
  216. Janicek MJ, Van den Abbeele AD, DeSisto WC, Kassis AI, Holman BL, Tumeh SS, Hollenberg NK. Embolization of platelets after endothelial injury to the aorta in rabbits. Assessment with 111indium-labeled platelets and angiography. Invest Radiol. 1991 Jul; 26(7):655-9.
    View in: PubMed
  217. Mariani G, Ito S, Nayak RC, Baranowska-Kortylewicz J, Venkateshan CN, Van den Abbeele AD, Eisenbarth GS, Adelstein SJ, Kassis AI. Capping and internalization of a monoclonal antibody-surface antigen complex: a possible mode of interaction of monoclonal antibodies and tumor cells. J Nucl Biol Med. 1991 Apr-Jun; 35(2):111-9.
    View in: PubMed
  218. Van den Abbeele AD, Aaronson RA, Daher S, Taube RA, Adelstein SJ, Kassis AI. Antigen-binding site protection during radiolabeling leads to a higher immunoreactive fraction. J Nucl Med. 1991 Jan; 32(1):116-22.
    View in: PubMed
  219. Adelstein SJ, Kassis AI, Baranowska-Kortylewicz J, Van den Abbeele AD, Mariani G, Ito S. . Potential for tumor therapy with iodine-125 labeled immunoglobulins. Nucl Medicine Biol. 1991; 18:43-4.
  220. Tumeh SS, Carvalho PA, van den Abbeele AD, Maguire JH, Rauh DA, Neptune M, Kassis AI. Detection of focal infection by 111In-human polyclonal IgG. J Nucl Biol Med. 1991 Jan-Mar; 35(1):4-9.
    View in: PubMed
  221. Adelstein SJ, Kassis AI, Baranowska-Kortylewicz J, van den Abbeele AD, Mariani G, Ito S. Potential for tumor therapy with iodine-125 labeled immunoglobulins. Int J Rad Appl Instrum B. 1991; 18(1):43-4.
    View in: PubMed
  222. Janicek MJ, Van den Abbeele AD, Hollenberg NK, Kassis AI, Holman BL, Tumeh SS. Platelet activation and aggregation after endothelial injury. Assessment with indium-111-labeled platelets and angiography. Invest Radiol. 1990 Sep; 25(9):988-93.
    View in: PubMed
  223. Kassis AI, Van den Abbeele AD, Wen PY, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LA, Black PM, Adelstein SJ. Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res. 1990 Aug 15; 50(16):5199-203.
    View in: PubMed
  224. Makrigiorgos GM, Ito S, Baranowska-Kortylewicz J, Vinter DW, Iqbal A, Van den Abbeele AD, Adelstein SJ, Kassis AI. Inhomogeneous deposition of radiopharmaceuticals at the cellular level: experimental evidence and dosimetric implications. J Nucl Med. 1990 Aug; 31(8):1358-63.
    View in: PubMed
  225. van den Abbeele AD, Aaronson RA, Taube RA, Adelstein SJ, Kassis AI. Preadsorption of radiolabeled monoclonal antibodies to liver and spleen tissues leads to higher tumor-to-normal-tissue ratios. J Nucl Med Allied Sci. 1990 Apr-Jun; 34(2):94-102.
    View in: PubMed
  226. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res. 1990 Apr 1; 50(7):2198-202.
    View in: PubMed
  227. Van den Abbeele AD, Wen PYC, Aaronson RA, Makrigiorgos GM, Morris JH, Baranowska-Kortylewicz J, Lampson LA, Black PM, Adelstein SJ, Kassis Al. Autoradiographic validation of 5-[123/125/] iodo-2'-deoxyurdine as a diagnostic and therapeutic agent for brain tumors. J Nucl Med,. 1990; 31(766).
  228. Makrigiorgos GM, Baranowska-Kortylewicz J, Van den Abbeele AD, Ito S, Vinter DW, Adelstein SJ, Kassis AI. Microscopic spatial inhomogeneity of radiopharmaceutical deposition in mammalian tissues: dosimetry at the cellular level and comparison with conventional dosimetry. Radiat Prot Dosim. 1990; 31:319-24..
  229. Muto MG, Lepisto EM, Van den Abbeele AD, Knapp RC, Kassis AI. Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. Am J Obstet Gynecol. 1989 Nov; 161(5):1206-12.
    View in: PubMed
  230. Kinsey BM, Van den Abbeele AD, Adelstein SJ, Kassis AI. Absence of preferential uptake of [125I]iododihydrorhodamine 123 by four human tumor xenografts. Cancer Res. 1989 Nov 1; 49(21):5986-8.
    View in: PubMed
  231. Weadock KS, Anderson LL, Van den Abbeele AD, Maktrigiorgos G, Kassis AI. . Radiolabeled biodegradable membranes for radioimmunotherapy. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer. 1989; 98.
  232. Borras-Boneu G, Knapp RC, Van den Abbeele AD, Kassis Al. Biodistribution of radiolabeled MOv18 in nude mice bearing ovarian cancer xenografts. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. 1989; 97.
  233. Weadock KS, Anderson LL, Van den Abbeele AD, Makrigiorgos G, Kassis Al. Radiolabeled biodegradable membranes for radioimmunotherapy. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. 1989; 98.
  234. Mariani G, Van den Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AL. Internalization of monoclonal 3G5-IgM by a rat insulinoma cell line. Nuclear medicine: trends and possibilities in nuclear medicine. 1989; 602-605.
  235. Mariani G, Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AI. Monoclonal antibody internalization by tumor cells: an experimental model for potential radioimmunotherapy applications. Int J Rad Appl Instrum B. 1989; 16(2):147-50.
    View in: PubMed
  236. Van den Abbeele AD, Aaronson RA, Adelstein SJ, Kassis AI. Does the in vitro testing of the immunoreactivity of an antibody reflect its in vivo behavior? J Nucl Med Allied Sci. 1988 Oct-Dec; 32(4):260-7.
    View in: PubMed
  237. Layne WW, Kassis AI, Van den Abbeele A, Kinsey BM, Adelstein SJ. HPLC analysis of the dissociation and recombination of rabbit immunoglobulin G. J Immunol Methods. 1987 Feb 11; 96(2):195-9.
    View in: PubMed
  238. Engelhardt B, Sandberg K, Bratton D, Van den Abbeele A, Grogaard J, Hellerqvist C, Sundell H. The role of granulocytes in the pulmonary response to group B streptococcal toxin in young lambs. Pediatr Res. 1987 Feb; 21(2):159-65.
    View in: PubMed
  239. Van den Abbeele AD, Hardoff R, Royal HD, Kolodny GM. Bone metastases in Zollinger-Ellison syndrome: detection by bone scintigraphy. Clin Nucl Med. 1987; 12:954-5..
  240. Van den Abbeele AD, Treves ST, Lebowitz RL, Bauer S, Davis RT, Retik A, Colodny A. Vesicoureteral reflux in asymptomatic siblings of patients with known reflux: radionuclide cystography. Pediatrics. 1987 Jan; 79(1):147-53.
    View in: PubMed
  241. Van den Abbeele A, Parker JA, Royal HD. Parathyroid scintigraphy. Division of Nuclear Medicine, Beth Israel Hospital, Harvard Medical School. 1986; 7(2).
  242. Grogaard J, Van den Abbeele A, Sundell H. Effect of alcohol on apnea reflexes in young lambs. J Appl Physiol. 1985 Aug; 59(2):420-5.
    View in: PubMed
  243. Van den Abbeele A, Solorzano C, Jones AG, Beardsley DS, Treves S, Davison A. Leukocyte labeling with isonitrile complexes of technetium-99m. J Nucl Med. 1985; 26:P131.
  244. Sundell HW, Rojas J, Grogaard J, Mohan P, Engelhardt B, Van den Abbeele A, Harris TR, Brigham KL. Lung lymph studies in newborn lambs with hyaline membrane disease. The physiological development of the fetus and newborn. 1985; 331-335.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Van Den Abbeele's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (414) concept(s)
_
Co-Authors
See all (104) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_